3AC

Toxicity: Standard Handling (A)

A cell-permeable steroidal compound that selectively inhibits SHIP1-, but not SHIP2-, catalyzed PI(3,4,5)P3-to-PI(3,4)P2 dephosphorylation (IC₅₀ = 10 µM vs. >1 mM, respectively), while exhibiting little activity against the PTEN-catalyzed PI(3,4,5)P3-to-PI(4,5)P2 conversion (IC₅₀ >1 mM). 3AC in vivo treatment (2.292 umol/200 µl/mouse/daily i.p. for 7 d) is reported to boost both peripheral blood granulocyte production (by 4- to 5-fold) and the GVHD- (graft-versus-host disease) suppressing Mac1⁺Gr1⁺ MIR (myeloid immunoregulatory) cell population in lymphoid tissues (by 5.55- and 11.53-fold in spleen and lymph nodes, respectively), resulting in an impaired splenocyte allogeneic T cell response in MLR (mixed-leukocyte/lymphocyte reaction) assays (by ≥95%). Similarly, 3AC-treated (9.4 µM; 24 h) primary human PBMCs greatly lose their ability in priming allogeneic T cell response in MLR assays (by 74.5%). In addition, a faster blood cell recovery is also observed in mice receiving 3AC (2.292 umol/200 µl/mouse/daily i.p. for 7 d) after sub-lethal irradiation (550 Rads). Selectively inhibits the growth and survival of SHIP1-dependent human KG-1 and murine C1498 myelogenous leukemia lines (IC₅₀ = 11.5 µM), but not the SHIP1-negative human CML K562 and osteosarcoma MG63 lines. SHIP2 Inhibitor, AS1938909 is also available (Cat. No. 565840).

Brooks, R., et al. 2010. J. Immunol.184, 3582.

Packaged under inert gas

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany